Inflammatory CNS Demyelination: Histopathologic Correlation with In Vivo Quantitative Proton MR Spectroscopy

References

1. ↵
   Lassmann H. Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis. Berlin, Heidelberg: Springer-Verlag; 1983
2. Prineas J. W. The neuropathology of multiple sclerosis. In: Koetsier, J. C. Demyelinating Diseases. Amsterdam: Elsevier Science Publishers; 1985;8:213-257
3. ↵
   Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of Multiple Sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6:259-274

   CrossRefPubMedWeb of Science
4. ↵
   McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992;18:319-334

   PubMedWeb of Science
5. ↵
   Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24

   Abstract/FREE Full Text
6. ↵
   Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-793

   CrossRefPubMedWeb of Science
7. ↵
   Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14:154-159

   PubMedWeb of Science
8. ↵
   Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118:1583-1592

   Abstract/FREE Full Text
9. ↵
   De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901-909

   CrossRefPubMedWeb of Science
10. Bruhn H, Gyngell ML, Merboldt KD, Hänicke W, Frahm J. Non-invasive assessment of brain lesions by fast scan MRI and localized proton spectroscopy. Neuroradiology 1991;33:S279-S281
11. Bruhn H, Frahm J, Merboldt KD, et al. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 1992;32:140-150

    CrossRefPubMedWeb of Science
12. ↵
    Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992;31:235-241

    CrossRefPubMedWeb of Science
13. Koopmans RA, Li DKB, Zhu G, Allen PS, Penn A, Paty DW. Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products. Lancet 1993;341:631-632

    CrossRefPubMedWeb of Science
14. ↵
    Frahm J, Hanefeld F. Localized proton magnetic resonance spectroscopy of brain disorders in childhood. In: Bachelard, H. S. Magnetic Resonance Spectroscopy and Imaging in Neurochemistry New York: Plenum Press 1997;12:329-402
15. Kim MO, Lee SA, Choi CG, Huh JR, Lee MC. Balo's concentric sclerosis: a clinical case study of brain MRI, biopsy, and proton magnetic resonance spectroscopic findings. J Neurol Neurosurg Psych 1997;62:655-658

    Abstract/FREE Full Text
16. ↵
    Silver NC, Barker RA, MacManus DG, et al. Proton magnetic resonance spectroscopy in a pathologically confirmed acute demyelinating lesion. J Neurol 1997;244:204-207

    CrossRefPubMedWeb of Science
17. ↵
    Davies SEC, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 1995;64:742-748

    PubMedWeb of Science
18. ↵
    Poser S, Lüer W, Bruhn H, Frahm J, Brück Y, Felgenhauer K. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 1992;86:579-585

    CrossRefPubMedWeb of Science
19. ↵
    Brück W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788-796

    CrossRefPubMedWeb of Science
20. ↵
    Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231

    CrossRefPubMedWeb of Science
21. Brück W, Schmied M, Suchanek G, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994;35:65-73

    CrossRefPubMedWeb of Science
22. ↵
    Colman DR, Kreibich G, Frey AB, Sabatini DD. Synthesis and incorporation of myelin polypeptides into CNS myelin. J Cell Biol 1982;95:598-608

    Abstract/FREE Full Text
23. ↵
    Breitschopf H, Suchanek G, Gould RM, Colman DR, Lassmann H. In situ hybridization with digoxigenin-labeled probes: sensitive and reliable detection method applied to myelinating rat brain. Acta Neuropathol 1992;84:581-587

    PubMed
24. ↵
    Mews I, Bergmann M, Bunkowski S, Gullotta F, Brück W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Multiple Sclerosis 1998;4:55-62

    Abstract/FREE Full Text
25. ↵
    Frahm J, Michaelis T, Merboldt KD, Bruhn H, Gyngell ML, Hänicke W. Improvements in localized ¹H-NMR spectroscopy of human brain. Water suppression, short echo times, and 1 mL resolution. J Magn Reson 1990;1990:464-473
26. ↵
    Michaelis T, Merboldt K-D, Bruhn H, Hänicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 1993;187:219-227

    PubMedWeb of Science
27. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679

    CrossRefPubMedWeb of Science
28. ↵
    Pouwels PJW, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 1998;39:53-60

    PubMedWeb of Science
29. ↵
    Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-399

    Abstract/FREE Full Text
30. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. New Engl J Med 1998;338:278-285

    CrossRefPubMedWeb of Science
31. De Stefano N, Matthews PM, Narayanan S, Francis GS, Antel JP, Arnold DL. Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 1997;49:1138-1141

    Abstract/FREE Full Text
32. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58

    Abstract/FREE Full Text
33. ↵
    Urenjak J, Williams SR, Gadian DG, Noble M. Proton magnetic resonance spectroscopy unambigously identifies different neural cell types. J Neurosci 1993;13:981-989

    Abstract
34. Bruhn H, Frahm J, Gyngell ML, et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989;172:541-548

    PubMedWeb of Science
35. ↵
    Jimenez JV, Richards TL, Heide AC, Grierson JR, Shankland EG. Incorporation of a phosphonium analogue of choline into the rat brain as measured by magnetic resonance spectroscopy. Magn Reson Med 1995;33:285-292

    CrossRefPubMed
36. ↵
    Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hänicke W, Sauter R. Localized proton NMR spectroscopy in different regions of the human brain in vivo: relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989;11:47-63

    PubMedWeb of Science
37. Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology 1991;41:1251-1256

    Abstract/FREE Full Text
38. ↵
    Brenner RE, Munro PMG, Williams SCR, et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Magn Reson Med 1993;29:737-745

    PubMedWeb of Science
39. ↵
    Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo ³¹P and ¹H spectroscopic imaging. Ann Neurol 1994;36:157-165

    CrossRefPubMedWeb of Science
40. Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119:715-722

    Abstract/FREE Full Text
41. ↵
    Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:189-198
42. Landtblom A-M, Sjöqvist L, Söderfeldt B, Nyland H, Thuomas K-A. Proton MR spectroscopy and MR imaging in acute and chronic multiple sclerosis—ringlike appearances in acute plaques. Acta radiol 1996;37:278-287

    PubMedWeb of Science
43. Pouwels PJW, Hanefeld F, Frahm J. Proton MRS in Pelizaeus-Merzbacher disease. Neuropediatrics 1997;23:355-356
44. Pan WP, Hetherington HP, Vaughan JT, Mitchell G, Pohost GM, Whitaker JN. Evaluation of multiple sclerosis by ¹H spectroscopic imaging at 4.1 T. Magn Reson Med 1996;36:72-77

    PubMedWeb of Science
45. ↵
    Lopez-Villegas D, Lenkinski RE, Wehrli SL, Ho W-Z, Douglas SD. Lactate production by human monocytes/macrophages determined by proton MR spectroscopy. Magn Reson Med 1995;34:32-38

    PubMed